Longboard Pharmaceuticals (LBPH) Income Statement (2021 - 2024)
Income Statement report data from Mar 31, 2021 to Sep 30, 2024 for Longboard Pharmaceuticals (LBPH).
Reported currency: USD
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||
Research And Development | 21M (+4.89%) | 20M (+55.28%) | 13M (+7.95%) | 12M (+16.30%) | 10M (-16.35%) | 13M (+47.01%) | 8.53M (-7.18%) | 9.19M (-2.23%) | 9.40M (+5.38%) | 8.92M (+25.28%) | 7.12M (+11.77%) | 6.37M (+55.75%) | 4.09M (-16.87%) | 4.92M (+11.82%) | 4.40M |
Selling General And Administrative | 6.67M (+28.27%) | 5.20M (+5.26%) | 4.94M (+46.15%) | 3.38M (+9.39%) | 3.09M (-0.64%) | 3.11M (-9.33%) | 3.43M (+35.57%) | 2.53M (+2.02%) | 2.48M (-6.42%) | 2.65M (+6.00%) | 2.50M (+2.88%) | 2.43M (+7.52%) | 2.26M (+9.18%) | 2.07M (+58.02%) | 1.31M |
Operating Expenses | 28M (+9.77%) | 26M (+41.78%) | 18M (+16.15%) | 16M (+14.71%) | 14M (-13.15%) | 16M (+30.83%) | 12M (+1.96%) | 12M (-1.18%) | 12M (+3.04%) | 12M (+19.73%) | 9.63M (+9.43%) | 8.80M (+38.15%) | 6.37M (-8.87%) | 6.99M (+22.63%) | 5.70M |
Operating Income | |||||||||||||||
Operating Income | -28.19M (+9.73%) | -25.69M (+41.78%) | -18.12M (+16.15%) | -15.60M (+14.71%) | -13.60M (-13.15%) | -15.66M (+30.83%) | -11.97M (+1.96%) | -11.74M (-1.18%) | -11.88M (+3.04%) | -11.53M (+19.73%) | -9.63M (+9.43%) | -8.80M (+38.15%) | -6.37M (-8.87%) | -6.99M (+22.63%) | -5.70M |
EBITDA | -28.19M (+9.73%) | -25.69M (+41.78%) | -18.12M (+16.15%) | -15.60M (+14.79%) | -13.59M (-13.22%) | -15.66M (+30.83%) | -11.97M (+2.05%) | -11.73M (-1.26%) | -11.88M (+3.04%) | -11.53M (+19.73%) | -9.63M (+9.43%) | -8.80M (+38.15%) | -6.37M (-8.87%) | -6.99M (+22.63%) | -5.70M |
Other Income / Expenses | |||||||||||||||
Interest Expense | 3.66M (-6.39%) | 3.91M (+24.92%) | 3.13M (+449.12%) | 570K (-13.64%) | 660K (0.00%) | 660K (+26.92%) | 520K (+33.33%) | 390K (+34.48%) | 290K (+123.08%) | 130K (+333.33%) | 30K (+50.00%) | 20K (0.00%) | 20K (+100.00%) | 10K | - |
Net Interest Income | -3.65M (-6.41%) | -3.90M (+24.60%) | -3.13M (+449.12%) | -570.00K (-13.64%) | -660.00K (0.00%) | -660.00K (+26.92%) | -520.00K (+33.33%) | -390.00K (+34.48%) | -290.00K (+123.08%) | -130.00K (+333.33%) | -30.00K (+50.00%) | -20.00K (0.00%) | -20.00K (+100.00%) | -10.00K | - |
Net Income | |||||||||||||||
Income Before Tax | -24.54M (+12.67%) | -21.78M (+45.30%) | -14.99M (-0.27%) | -15.03M (+16.24%) | -12.93M (-13.80%) | -15.00M (+30.89%) | -11.46M (+1.06%) | -11.34M (-2.24%) | -11.60M (+1.67%) | -11.41M (+18.85%) | -9.60M (+9.46%) | -8.77M (+38.33%) | -6.34M (-9.17%) | -6.98M (+22.46%) | -5.70M |
Net Income From Continuing Operations | -24.54M (+12.67%) | -21.78M (+45.30%) | -14.99M (-0.27%) | -15.03M (+16.24%) | -12.93M (-13.80%) | -15.00M (+30.89%) | -11.46M (+1.06%) | -11.34M (-2.24%) | -11.60M (+1.67%) | -11.41M (+18.85%) | -9.60M (+9.46%) | -8.77M (+38.33%) | -6.34M (-9.17%) | -6.98M (+22.46%) | -5.70M |
Net Income | -24.54M (+12.67%) | -21.78M (+45.30%) | -14.99M (-0.27%) | -15.03M (+16.24%) | -12.93M (-13.80%) | -15.00M (+30.89%) | -11.46M (+1.06%) | -11.34M (-2.24%) | -11.60M (+1.67%) | -11.41M (+18.85%) | -9.60M (+9.46%) | -8.77M (+38.33%) | -6.34M (-9.17%) | -6.98M (+22.46%) | -5.70M |